Friday, February 14, 2014

Muchkins & Mammograms Is Back!

Triple Pink Foundation once again is partnering with Dunkin’ Donuts® to present a unique breast cancer awareness event - Munchkins® & Mammograms.  The event will take place on Saturday, May 10, 2014 at the Brookhaven Dunkin’ Donuts, 4040 Peachtree Street NE, Atlanta 30319.  

Munchkins & Mammograms flyer

We are so busy during the week with work and family that our health usually takes a backseat.  Munchkins® & Mammograms gives you a convenient way to get your annual mammograms.  And it's the best Mother's Day gift you can give to yourself!  

Each woman who receives a mammogram also will receive free Munchkins®.  Think of it as a way to sweeten the experience.  

The mammograms will be performed by St. Joseph’s Mobile Mammography Coach from 9:00 a.m. until 3:00 p.m.  The service is provided at no or low cost to patients with approved insurance providers.  Most insurance providers are accepted by St. Joseph’s.  Pre-registration must be completed by April 18, 2014.  

For more information and to schedule an appointment, contact Triple Pink at:

Thursday, August 2, 2012


A couple of weeks ago, I had my annual mammogram. They had become routine for me – nothing special, just the regular smashing of my girls between two plastic plates. Normally, I receive a letter after the exam stating that everything was normal, and I schedule the exam for next year.

But this time, I received a letter stating that I needed to have a diagnostic (follow-up) mammogram.
This is not the kind of news anyone wants to receive, especially not a breast cancer survivor.
The days leading up to the diagnostic felt like weeks.

I finally had the follow-up mammogram (6 years to the month of when I had chemotherapy in 2006). While I waited for the results, I thought about my life now versus what my life was like when I went through the process years ago. I wasn’t married then, was a newly minted lawyer, and had only been in Atlanta for a year. Before I continued my walk down memory lane, the nurse returned and told me that the results were NORMAL!

"your exam shows nothing to indicate breast cancer"
 I sat there for a moment staring at the normal exam report that had become so routine for me in the last few years and appreciated how much of a blessing it is. It was also during that moment that I decided to share my 2006 journey with you - beginning with chemo, to losing my hair, and having surgery. So stay tuned for upcoming posts.

Wednesday, July 25, 2012

New Breast Cancer Drug Afinitor Shows Trend Of Extending Survival

Novartis received approval last week for Afinitor to be used to combat breast cancer.  The drug already has approval for tumors of the kidney and pancreas. 
It's showing more significant benefit, but it's also not making people as sick as some of the other therapies.
Click here to

Friday, July 6, 2012

Triple Pink Turns 5!

Today marks Triple Pink's 5th Anniversary

We're so grateful for the awesome support that we've received from all of our volunteers and donors.  We have been very fortunate to sponsor some great programs in the past and are looking forward to another 5...make that, 50+ years!  

Wednesday, June 13, 2012

New Weapon In The Arsenal Against HER-2 Positive Breast Cancer

Photo Credit:  Genetech
 The FDA recently approved a new drug developed by Roche pharamaceuticals for the treatment of HER-2 positive breast cancers.  Perjeta was accepted by the FDA for priority review, indicating that the drug presents a significant advantage over existing treatments.  During clinical trials for advanced breast cancer, the drug significantly delayed the cancer from worsening, compared to the existing standard of care. 

In addition to the approved Perjeta, Roche also is developing T-DM1, which is designed to combine a type of chemotherapy to Herceptin.  The drug is in Phase III trials and is being developed for treatment of HER-2 positive breast cancers. 

Read more:

Thursday, June 7, 2012

Breakthrough In Triple Negative: DNA Marker Discovered

Researchers at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research in New York have discovered a DNA marker linked to triple-negative breast cancer that's helping them to determine why African-American women often experience this more aggressive form of the disease. 

Read more about this exciting development:

Friday, June 1, 2012